Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
As of close of business last night, Dexcom Inc’s stock clocked out at $113.69, up 2.51% from its previous closing price of $110.91. In other words, the price has increased by $2.51 from its previous closing price. On the day, 1.35 million shares were traded. DXCM stock price reached its highest trading level at $113.83 during the session, while it also had its lowest trading level at $110.03.
Ratios:
To gain a deeper understanding of DXCM’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 15.61 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 77.48. For the most recent quarter (mrq), Quick Ratio is recorded 2.53 and its Current Ratio is at 2.90. In the meantime, Its Debt-to-Equity ratio is 1.15 whereas as Long-Term Debt/Eq ratio is at 1.14.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Redburn Atlantic on May 30, 2024, initiated with a Neutral rating and assigned the stock a target price of $130.
On March 12, 2024, RBC Capital Mkts started tracking the stock assigning a Outperform rating and target price of $165.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jun 28 ’24 when Brown Michael Jon sold 659 shares for $114.29 per share. The transaction valued at 75,317 led to the insider holds 66,901 shares of the business.
FOLETTA MARK G sold 3,306 shares of DXCM for $386,122 on Jun 18 ’24. The Director now owns 56,398 shares after completing the transaction at $116.79 per share. On Jun 17 ’24, another insider, FOLETTA MARK G, who serves as the Director of the company, sold 2,694 shares for $117.26 each. As a result, the insider received 315,907 and left with 59,704 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DXCM now has a Market Capitalization of 45212696576 and an Enterprise Value of 44905775104. As of this moment, Dexcom’s Price-to-Earnings (P/E) ratio for their current fiscal year is 73.40, and their Forward P/E ratio for the next fiscal year is 50.41. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 4.07. For the stock, the TTM Price-to-Sale (P/S) ratio is 11.89 while its Price-to-Book (P/B) ratio in mrq is 20.04. Its current Enterprise Value per Revenue stands at 11.812 whereas that against EBITDA is 52.924.
Stock Price History:
Over the past 52 weeks, DXCM has reached a high of $142.00, while it has fallen to a 52-week low of $74.75. The 50-Day Moving Average of the stock is -7.07%, while the 200-Day Moving Average is calculated to be -2.49%.
Shares Statistics:
It appears that DXCM traded 2.81M shares on average per day over the past three months and 3342700 shares per day over the past ten days. A total of 397.68M shares are outstanding, with a floating share count of 391.50M. Insiders hold about 1.55% of the company’s shares, while institutions hold 93.79% stake in the company. Shares short for DXCM as of 1718323200 were 9009590 with a Short Ratio of 3.21, compared to 1715731200 on 7783693. Therefore, it implies a Short% of Shares Outstanding of 9009590 and a Short% of Float of 2.56.
Earnings Estimates
The market rating of Dexcom Inc (DXCM) is currently shaped by the ongoing analysis conducted by 20.0 analysts closely monitoring its performance.On average, analysts expect EPS of $0.39 for the current quarter, with a high estimate of $0.42 and a low estimate of $0.34, while EPS last year was $0.34. The consensus estimate for the next quarter is $0.51, with high estimates of $0.55 and low estimates of $0.48.
Analysts are recommending an EPS of between $1.89 and $1.67 for the fiscal current year, implying an average EPS of $1.79. EPS for the following year is $2.26, with 22.0 analysts recommending between $2.57 and $2.04.
Revenue Estimates
In the current quarter, 20 analysts expect revenue to total $1.04B. It ranges from a high estimate of $1.05B to a low estimate of $1.03B. As of the current estimate, Dexcom Inc’s year-ago sales were $841.62MFor the next quarter, 20 analysts are estimating revenue of $1.15B. There is a high estimate of $1.18B for the next quarter, whereas the lowest estimate is $1.13B.
A total of 25 analysts have provided revenue estimates for DXCM’s current fiscal year. The highest revenue estimate was $4.37B, while the lowest revenue estimate was $4.28B, resulting in an average revenue estimate of $4.33B. In the same quarter a year ago, actual revenue was $3.62BBased on 25 analysts’ estimates, the company’s revenue will be $5.16B in the next fiscal year. The high estimate is $5.4B and the low estimate is $4.97B.
